mut

MUT056399 (Fab-001) is a highly potent inhibitor of the FabI enzyme in both S. aureus and E. coli, with IC50 values of 12 nM and 58 nM, respectively.

T100-Mut is a cell-penetrating peptide that penetrates and targets the inner side of the cytoplasmic membrane by binding its N-terminus to a myristoyl group, thus mimicking the topology of Tmem100-3Q. T100-Mut can alleviate TRPA1-related pain.

N36Mut(e,g) is an HIV fusion peptide inhibitor targeting gp41. It functions by disrupting the formation of the homotrimeric coiled coil of the N-terminal helix in the pre-hairpin intermediate, leading to the creation of a heterotrimer.

Mutant IDH1-IN-2 is an inhibitor of mutant Isocitrate dehydrogenase (IDH) proteins, with an IC50 of 16.6 nM in fluorescence biochemical assay and an IC50 of <22 nM in LS-MS biochemical assay.

Bismuth Subsalicylate (Bismuth subsalicylat) is the active ingredient in the popular medication Pepto-Bismol that is used to treat nausea, heartburn, indigestion, upset stomach, diarrhea, and other temporary discomforts of the stomach and gastrointestinal tract.

Mutated EGFR-IN-1 (Osimertinib analog) is a valuable intermediate in designing inhibitors for mutated EGFR, including L858R EGFR, Exon19 deletion activating mutant, and T790M resistance mutant.

Pleuromutilin (Drosophilin B) is an inhibitor of bacterial protein synthesis by binding to the 50S ribosomal subunit of bacteria.

Triphenyl bismuth (NSC-465) is an additive for making biomedical resins visible on x-ray images and can be used as a radiopaque agent for orthopaedic bone cements.

Bismuth subgallate (Dermatol Puder) is an astringent and antiseptic and is applied to skin diseases such as eczema.

Lemuteporfin is a light-activated photosensitizing agent that is rapidly internalized by viable cells, localizing within the cytoplasm and associating with mitochondria. This localization is a key characteristic that confers strong cytotoxic potential upon light activation. Lemuteporfin has demonstrated the ability to reduce sebaceous gland volume in preclinical animal studies. It is currently under investigation in relation to benign prostatic hyperplasia and in topical form for the management of androgenetic alopecia.

Mutant IDH1-IN-1 is a potent inhibitor of the mutant IDH1 R132 h, exhibiting an IC50 of less than 0.1 μM.

EGFR mutant- in-1, A 5-methylpyrimidopyridone derivative are effective selective EGFRL858R/T790M/C797S mutant inhibitors with IC50 of 27.5 nM, which significantly weakened EGFRWT effect.

Mutant IDH1-IN-4 is an mutant Isocitrate dehydrogenase 1 (IDH 1) inhibitor.

Mutated EGFR-IN-2 is an inhibitor of mutant-selective EGFR.

Mutated EGFR-IN-3 is a ATP-competitive and highly selective allosteric dibenzodiazepinone EGFR(L858R/T790M) and EGFR(L858R/T790M/C797S) inhibitor(IC50 of 12 nM and 13 nM, respectively. )

RAF mutant-IN-1 is an inhibitor of RAF kinase(IC50 values of 21 nM, 30 nM and 392 nM for C-RAF 340D/Y341D, B-RAFV600E and B-RAFWT, respectively).

Mutant IDH1 inhibitor is an effective inhibitor of mutant IDH1 R132H (IC50: < 72 nM).

Elatipepimut-S falls under the category of antitumor compounds.

Mutant IDH1-IN-3 (Compound 1) is a selective allosteric inhibitor targeting the mutant isocitrate dehydrogenase 1 (IDH1), with an IC50 of 13 nM for R132HIDH1. It effectively suppresses the production of D-2-hydroxyglutarate (2HG) in cells and is applicable for research in oncology.

Bismuth(III) oxide is a common starting point for bismuth chemistry. It is usually obtained as a by-product of the smelting of copper and lead ores. Bismuth trioxide is commonly used as a replacement of red lead to produce the "Dragon's eggs" effect in fi

Mutant IDH1/NAMPT-IN-1 (Compound 23h) is a dual inhibitor of mutant isocitrate dehydrogenase 1 (mutantIDH1) with an IC50 of 14.93 nM, and nicotinamide phosphoribosyltransferase (NAMPT) with an IC50 of 12.56 nM. This compound can induce apoptosis and effectively crosses the blood-brain barrier.

Mutant IDH1-IN-7 is a highly selective inhibitor of Isocitrate Dehydrogenase 1 (IDH1) with R132H mutation (IC50 = 0.26 μM, Kd = 2.1 μM) and R132C mutation (IC50 = 1.1 μM). It does not inhibit wild-type IDH1, IDH2-wt, or IDH2R140Q. Moreover, Mutant IDH1-IN-7 reduces the production of 2-hydroxyglutarate (2-HG) in U87-MG R132H cells (EC50 = 0.55 μM) and exhibits moderate antiproliferative effects on U87-MG R132H and HT-1080 cells.

Mutant EGFR inhibitor is a selective and potent Mutated EGFR inhibitor, inhibits L858R activating mutant, the Exonl9 deletion activating mutant and the T790M resistance mutant.

Bismuth camphocarbonate is used for herpes zoster.